

## Hull and East Riding Prescribing Committee Minutes – Unconfirmed

**Date / Time** Wednesday 27<sup>th</sup> April 2022, 1pm  
**Venue** WEBEX  
**Chair** Dr S Raise, GP Prescribing Lead, ERY CCG  
**Notes / Action Points** Mr Luke Storr, Senior Technician – Interface HUTH  
**Quorate: Yes / No** Yes

Miss J Morgan, Principal Pharmacist - Interface, HUTH  
Dr B Ali, GP Prescribing Lead, ER CCG  
Mr K McCorry, Senior Pharmacist, NECS  
Ms M Opoku-Fofie, Deputy Chief Pharmacist, HFTH  
Prof A Morice, Professor of Respiratory Medicine, HUTH  
Mrs C Haywood, Professional Development Lead, LPC  
Ms J Goode, Chief Pharmacist, HUTH  
Mrs E Baggaley, Head of Medicines Service, CHCP  
Mr A Ortiz-Moya, Interim Principal Pharmacist MH & LD Services, HFTH

**Apologies** Dr R Schreiber – Medical Secretary LMC  
Mr P Davis, Strategic Lead Primary Care, Hull, CCG

**In attendance** Luke Storr, Interface Technician, HUTH

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date/Date complete
2022.04.01	Apologies	As above				
2022.04.02	Declarations of Interest	None				
2022.04.03	Minutes of the Previous Meeting	Accepted as a true record				
2022.04.04	Matters Arising & Action Tracker	<p><b>Correspondence Received</b> Rheumatology to prepare pathway with rituximab without MTX- Pathway still in draft form- Rheumatology pharmacist to meet with Dr Ogumbambi and confirm pathway. No further correspondence from Rheumatology.</p> <p><b>Feedback From Commissioning Groups</b> KMc and JM to work with CCG to approve MS guideline- JM/Dr Harley to attend pathway review group and feedback</p> <p><b>Hydroxychloroquine SCF</b> JM to discuss ophthalmology checks with rheumatology. JM to add Harrogate pathway to agenda when published.</p> <p><b>AOB</b> Diabetes guideline – JM to review diabetes guideline when NICE publish and discuss with Diabetologists</p> <p><b>Traffic Light Status</b> JM to update formulary and red list</p> <p><b>Prescribing guidelines – UTI guidance</b> JM to update current guidance to remove old UTI guidance and add new guidance to website. JM to finish- Updated and sent to web services</p> <p><b>Prescribing guidelines – Dienogest pathway</b> JM to confirm prescribing arrangements with specialist team. JM spoken to specialist nurse and outlined them to prescribe the first 3 months of treatment, review then communicate to primary care for continuation of treatment via template letter. JM not received any further response, JM to chase</p> <p><b>Prescribing guidelines – Secondary prevention pathways for lipid lowering therapies</b> JM to if LDL-C is needed before the specialist referral and to prepare</p>	<p>Update next time</p> <p>Update next time</p> <p>On agenda</p> <p>Update next time</p> <p>Action complete</p> <p>Action complete</p> <p>JM to contact specialist again</p> <p>On agenda</p>	<p>Ongoing- Pass on to APC</p> <p>Ongoing- Pass on to APC</p> <p>On agenda</p> <p>Ongoing- pass on to APC</p> <p>No further actions</p> <p>No further action</p> <p>Ongoing- pass on to APC</p>	<p>JM</p> <p>JM</p> <p>JM</p> <p>JM</p> <p>JM</p> <p>JM</p> <p>JM</p>	<p>Apr 22</p> <p>Aug 22</p> <p>Sep 21</p> <p>Apr 22</p> <p>Apr 22</p> <p>Apr 22</p> <p>Apr 22</p>

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date/Date complete
		<p>SCF for Inclisiran in conjunction with specialist team- On agenda, JM has started preparing guidance.</p> <p><b>Prescribing guidelines - Renal analgesic ladder</b> To upload on HERPC website with web services</p> <p><b>Prescribing guidelines – update ticagrelor 60mg</b> To upload on HERPC website with web services</p> <p><b>Prescribing guidelines - Prescribing medicines in pregnancy</b> To remove old prescribing guideline in pregnancy and update webpage with SPS information and disclaimer regarding HUTH guidance. JM sent to web services</p> <p><b>Prescribing guidelines – Renal transplant medicines</b> JM to update with alternative H2 receptor antagonist and review plan for renal repatriation. JM has emailed renal but not reply JM to email NHSE</p> <p><b>Traffic Light Status</b> LS to update joint formulary and red list</p> <p><b>Prescribing guidelines, shared care frameworks for approval</b> JM to upload approved guidance/pathways onto HERPC websites</p> <p><b>Prescribing guidelines, shared care frameworks for approval</b> GMc to confirm FP10 charging info for wound management and compression formularies. Confirmed that FP10 would be charged to CCG</p> <p><b>Prescribing guidelines, shared care frameworks for approval</b> GMc to confirm if a tool is used to assess for need of a compression donning aids. No tool is used and aids normally come with stockings but nursing staff asses how well the patient would be able to cope.</p> <p><b>Prescribing guidelines, shared care frameworks for approval</b> Systemic biological therapies for psoriasis – JM to confirm how they choose initial therapy</p>	<p>Action complete</p> <p>Action complete</p> <p>Action complete</p> <p>JM to contact renal</p> <p>Action complete</p> <p>Action complete</p> <p>Action complete</p> <p>Action complete</p> <p>On agenda</p>	<p>No further action</p> <p>No further action</p> <p>No further action</p> <p>Ongoing- pass on to APC</p> <p>No further action</p> <p>No further action</p> <p>No further action</p>	<p>JM</p> <p>JM</p> <p>JM</p> <p>JM</p> <p>JM</p> <p>JM</p> <p>GMc</p> <p>GMc</p>	<p>Apr 22</p> <p>Apr 22</p> <p>Apr 22</p> <p>Apr 22</p> <p>Apr 22</p> <p>Apr 22</p> <p>Apr 22</p> <p>Apr 22</p>
2022.04.05	Traffic Light Status	<p>Luforbec 100/6 MDI- proposed as BLUE Cabotegravir with rilpivavine (separate agents, prolonged release injection and tablets) proposed as RED</p>	Approved	RED list to be updated and joint formulary	LS	Apr 22

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date/Date complete
		<p>Crizanulizumab proposed as RED  Dostarlimab proposed as RED  Misoprostol (25 microg tablets) proposed as RED  Progesterone vaginal capsules proposed as RED  Fremanezumab- updated TA- proposed as RED  Upadactinib- new TA- proposed as RED  Dapaglifozin- new TA- proposed as BLUE  Empaglifozin- new TA- proposed as BLUE  Mexiletine- licensed product now available- proposed as BLUE, agreed to stay RED  Bismuth subsalicylate proposed as BLUE  Sodium chloride 3% nebulas proposed as BLUE  Ofloxacin tablets- as per infection guidance- proposed as BLUE</p>		to be updated		
2022.04.06	Feedback From Commissioning Groups	<p><b>ERoY CCG</b></p> <ol style="list-style-type: none"> <li>HUTH D&amp;T: December 2021 - approved</li> <li>Primary care guidelines – Urinary tract infection chapter (update) - approved</li> <li>Commissioning recommendations for national procurement for direct acting oral anticoagulants (DOACs) (decide from options) – agreed Edoxaban option for new patients and other DOAC options in order as per the NHSE/I document.</li> </ol> <p><b>Hull CCG and ERoY CCG</b></p> <p>Both CCGs have approved MO work plan for 2022/23</p>	Noted	No further action		Mar 22
2022.04.07	Prescribing guidelines, shared care frameworks for approval	<p><b>New:</b>  <b>Inclisiran guidance-</b> used in conjunction with lipid guidance. Discussed why proposed as BLUE specialist lead but guidance wording a bit confusing on when it can be prescribed and by whom. Wording at beginning of guidance to be changed to clarify when primary care can prescribe.</p> <p><b>Updates:</b>  <b>Prescribing Anticoagulants –</b> JM updated guidelines with reference to NHSE but no link as unable to find one. Order of anticoagulants currently in alphabetical though BA raised point that edoxaban should be at the top as it is now 1<sup>st</sup> line treatment, this will help prescribers.</p> <p><b>Humber High Dose Antipsychotics guidance-</b> Minor changes in</p>	JM to update	No further action	JM	May 22
			JM to update	No further action	JM	May 22
			Action complete	No further	JM	Apr 22

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date/Date complete
		<p>respect to working practice with the new use of electronic prescribing (ePMA) updated ready reckoner.</p> <p><b>Pathway updates:</b>  <b>Psoriasis pathway-</b> addition of reference. Update on how to choose treatment. First line is a biologics but if needle phobic or cannot tolerate biologic then Apremilast/Dimethyl fumarate. Pathway still confusing. Suggested to update with "if not appropriate" to clarify.</p>	JM to update	<p>action</p> <p>No further action</p>	JM	May 22
2022.04.08	MHRA DSU	<ul style="list-style-type: none"> <li><a href="#">March</a></li> <li><a href="#">April</a> – Pregabalin update, MHRA now have a warning leaflet for women of childbearing potential and the risks of malformation during pregnancy.</li> </ul>	Noted JM to discuss with HUTH and circulate	Pregabalin action to be passed to APC	JM	June 22
2022.04.09	Regional Medicines Optimisation Committee	Nil this month	Noted	No further action		Apr 22
2022.04.10	Correspondence Received	<b>Hydroxychloroquine West Yorkshire Health and Care Partnership Pathway-</b> Mr Vize happy with pathway. JM to present to business managers for ophthalmology.	JM to contact specialist	Pass on to APC		Sep 22
2022.04.11	Primary Care Rebate Scheme	Nil this month	Noted	No further action		Apr 22
2022.04.12	Additional Minutes for Information	<ul style="list-style-type: none"> <li>a) MMIG</li> <li>b) HUTH D&amp;T</li> <li>c) HTFT DTC</li> <li>d) CHCP</li> <li>e) Formulary Sub Group</li> <li>f) Hull CC Planning &amp; Commissioning</li> </ul>	Noted	No further action		Apr 22
2022.04.13	Actions for Humber Area Prescribing Committee	Noted above	Noted			
2022.04.14	A.O.B	<p><b>MO wished to discuss SCF Dementia-</b> Updated pathway. MO and AO presented the updated framework with contact details for the specialist services for a GP to contact for advice and potential referral back to specialist service.</p> <p>BA raised concerns that GP may not be able to have time to contact the specialist service and that the specialist service may not be able to give advice all the time.</p> <p>Discussed further between committee and decided that framework</p>	Document to be updated and presented to APC	Update document and circulate to stakeholders. Discuss at APC	MO/AO JM/EB	Jun 22

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date/Date complete
		<p>needs clarification with wording and contact e-mails</p> <p><b>Lithium SCF</b></p> <p>AO raised the Lithium SCF was updated with specific care plan for Lithium that is now used within Humber. This minor change has been made to SCF and uploaded onto the website to enable use of the most recent version of SCF. SCF approved.</p>	Approved	No further action		
	<b>Date and Time of Next Meeting</b>	Final meeting				